OncoKB

Overview

Precision oncology knowledge base curating the oncogenic effect and clinical actionability of somatic alterations across cancer types.

Used by

  • PMID:36357680 — used in the NSCLC ctDNA-guided therapy cohort to annotate alterations and identify patients matched to targeted therapy by ctDNA sequencing; 255/722 (23%) ctDNA-positive patients matched to targeted therapy had longer OS than ctDNA-positive patients not receiving targeted therapy (HR 0.63, 95% CI 0.52–0.76, P<0.001) PMID:36357680.
  • PMID:36493333 — used to annotate oncogenic drivers and actionable variants in the appendiceal adenocarcinoma MSK-IMPACT cohort, supporting the GNAS/RAS/TP53-defined MAAP subtype framework PMID:36493333.
  • PMID:37682528 — used to classify FGFR3/FGFR2 alterations as oncogenic/actionable across 1,507 urothelial carcinoma tumors, defining the denominator for erdafitinib eligibility and filtering acquired cfDNA variants (TP53, AKT1, FGFR3 V553M/N540S) for putative resistance calls PMID:37682528.
  • PMID:37643132 — OncoKB v3.1.4 used to annotate actionability in 177 cervical cancer patients sequenced by MSK-IMPACT; 20% had level 1/2 actionable alterations including PIK3CA and ERBB2 PMID:37643132.
  • PMID:37651310 — OncoKB used to annotate oncogenic and actionable variants in 1,882 endometrial carcinoma patients from MSK PMID:37651310.
  • PMID:37769223 — OncoKB used for variant annotation in 51 HCC patients profiled by MSK-ACCESS cfDNA; 4/10 (40%) cfDNA-exclusive alterations were OncoKB level 3b actionable PMID:37769223.
  • PMID:39289779 — OncoKB used to classify variants (levels 1–4 and resistance R1/R2) in 1,007 CSF cfDNA samples; 50.7% of ctDNA-positive samples carried a level 1 OncoKB actionable alteration; lung carcinomas had the highest level 1 actionability PMID:39289779.
  • PMID:39506116 — OncoKB used to annotate oncogenicity and clinical actionability of somatic alterations across 24,950 MSK-CHORD patients; variants classified for downstream multimodal survival and metastasis-tropism analyses PMID:39506116.
  • PMID:39753968 — OncoKB v4.12 (Dec 2023) used to annotate all somatic alterations in 2,336 PAAD patients; ~10% of patients harbored OncoKB level 1 or 2 biomarkers; an additional 78% met level 3A based on KRAS G12D/V/R/A/S reflecting the emerging RAS-inhibitor pipeline PMID:39753968.
  • Used to annotate variants in 244 GBC samples; identified actionable alterations in 35% of patients (OncoKB levels 1, 3A, or 3B), including NTRK1 fusions (level 1) and ERBB2 amplifications (level 3B) PMID:36228155
  • Used OncoKB to annotate clinical actionability of somatic variants in pediatric cancer PMID:28445112
  • OncoKB actionability tiers applied to MSK-IMPACT results; 36.7% of 10,336 patients harbored at least one actionable alteration, with GIST (76%), thyroid (60%), breast (57%), and melanoma (56%) having the highest rates PMID:28481359

Notes

  • Frequently paired with MSK-IMPACT or other targeted panels in the corpus to translate raw variant calls into clinically interpretable alteration calls PMID:36493333.

Sources

This page was processed by crosslinker on 2026-05-06. - PMID:36228155

This page was processed by crosslinker on 2026-05-06. - PMID:28445112

This page was processed by wiki-cli on 2026-05-14. - PMID:28481359

This page was processed by wiki-cli on 2026-05-15.